WEEKEND NEWS
SOPHiA GENETICS Presents Ground-Breaking Multimodal Research on AI-Driven Patient Stratification at ESMO 2024
SOPHiA GENETICS (Nasdaq: SOPH) will present groundbreaking research at ESMO 2024, showcasing AI-driven patient stratification for non-small cell lung cancer (NSCLC) treatment.
The study, conducted with AstraZeneca, analyzed the POSEIDON Phase 3 clinical trial using multimodal machine learningto identify NSCLC patient subgroups most likely to benefit from combination immunotherapy.
The research revealed signatures associated with higher overall survival benefit from adding tremelimumab to durvalumab and chemotherapy in first-line treatment of metastatic NSCLC.
Key genetic factors included EGFR wild-type, FGFR3 wild-type, CDKN2A wild-type, KRAS mutation, and STK11 mutation.
This approach could significantly impact NSCLC treatment by enabling more personalized care strategies.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
2536Followers
107Following
27KVisitors
Follow